Reducing animal use in monoclonal antibody development

Since the late 1990’s the number of monoclonal antibodies (mAbs) entering the clinic has increased substantially as companies exploit the potential benefits to patients offered by these new biotherapeutics. The nonclinical testing of mAbs poses some challenges because their high degree of target specificity can mean that there is either no relevant species to use or the non-human primate is the only option. We have a comprehensive programme to reduce the use of animals in monoclonal antibody (mAb) development, whilst supporting the drug development process and patient safety.

Non-human primates | Rodents | Biosimilars 

Non-human primates

We have worked with the international pharmaceutical and biotechnology industry to embed the 3Rs in the development of mAbs - minimising the use of non-human primates and influencing the addendum to the ICH S6 guidelines on the nonclinical safety evaluation of biotechnology-derived pharmaceuticals.

We have focused on opportunities to reduce the use of non-human primates by facilitating cross-company data sharing on group sizes, and the number of doses, recovery animals and studies carried out. Our analysis of over 100 compounds from 15 companies has provided the scientific rationale to halve the number of non-human primates used in a typical mAb development programme from 144 to 64. This is based on using group sizes of three males and three females, rather than four of each sex; including fewer recovery animals; dropping the medium dose group; and reducing the number of studies from three to two with a short-term study to support first-in-human trials and a six month study to support registration.

We are also supporting research through our CRACK IT Challenges funding competition, working with scientists at Huntingdon Life Sciences and the University of Southampton to develop predictive in vitro systems for assessing the risk of antibody-induced cytokine release (‘cytokine storms’) in humans, which would usually be investigated in non-human primates.


With the recent shift in industry to selecting mAbs with potency in rodents we have also started to focus on maximising the information derived from the rat or mouse to further minimise the use of non-human primates and to avoid the risk of a two species approach becoming common practice for safety studies. This was launched with a joint symposium with Charles River Laboratories in Carlsbad, USA, in 2013 which highlighted the use of rodent studies in mAb development and the requirement for improved bioanalysis and microsampling technologies to reduce the number of animals used


The importance of establishing data-driven recommendations on non-human primate numbers has been highlighted by recent approvals of biosimilars, that is, generic versions of currently used mAbs. Testing requirements for approval of biosimilars differ widely from one country to another with some requiring extensive animal testing. Many biosimilars are manufactured in countries outside the reach of the ICH. Working with the Medicines and Healthcare Products Regulatory Agency and 13 companies we are now examining the need for in vivo studies when the biosimilar and innovator product are indistinguishable by a variety of in vitro test methods.






Workshop report: NC3Rs/ABPI (2006) Opportunities for reducing the use of non-human primates in the development of monoclonal antibodies a workshop report. London: NC3Rs/ABPI

Chapman K., et al. (2007). Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nature Reviews Drug Discovery 6(2): 120-126. doi:10.1038/nrd2242

Chapman K.,  et al. (2009). Preclinical development of monoclonal antibodies: considerations for the use of non-human primates. MAbs 1(5): 505-516. doi:10.4161/mabs.1.5.9676

Chapman K., et al. (2010). The future of non-human primate use in mAb development. Drug Discovery Today 15(5-6): 235-242. doi:10.1016/j.drudis.2010.01.002

Buckley L., Chapman K., et al. (2011). Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals. International Journal of Toxicology 30(5): 583-590. doi:10.1177/1091581811415875

Chapman K., et al. (2012). The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primates. Regulatory Toxicology and Pharmacology 62(2):347-54. doi:10.1016/j.yrtph.2011.10.016

Chapman K., et al. (2016) Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges. mAbs 8(3): doi: 10.1080/19420862.2016.1145331

Poster presented at the NC3Rs Toxicology Showcase, September 2016: Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges

Back to top